Suchergebnisse - "Hasselbalch, Hans Carl"

PubPharm (236)

101

Smoking and philadelphia‐negative chronic myeloproliferative neoplasms

enthalten in: European journal of haematology | 2016

von Lindholm Sørensen, A. | Hasselbalch, H.

102

Chronic inflammation and autoimmunity as risk factors for the development of chronic myelomonocytic leukemia?

enthalten in: Leukemia & lymphoma | 2016

von Elbæk, M. | Sørensen, A. | Hasselbalch, H.

103

Increased iron stores prolong the QT interval – a general population study including 20 261 individuals and meta‐analysis of thalassaemia major

enthalten in: British journal of haematology | 2016

von Henriksen, L. | Petri, A. | Hasselbalch, H. | +2

104

Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms

enthalten in: European journal of haematology | 2016

von Hansen, I. | Sørensen, A. | Hasselbalch, H.

105

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms

enthalten in: Leukemia & lymphoma | 2016

von Skov, V. | Riley, C. | Thomassen, M. | +5

106

A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms

enthalten in: Quality of life research | 2015

von Brochmann, N. | Zwisler, A. | Kjerholt, M. | +3

107

Smoking as a contributing factor for development of polycythemia vera and related neoplasms

enthalten in: Leukemia research | 2015

von Hasselbalch, H.

108

Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?

enthalten in: Expert review of hematology | 2015

von Hasselbalch, H. | Silver, R.

109

Survival of patients with chronic myeloproliferative neoplasms and new primary cancers : a population-based cohort study

enthalten in: The Lancet. Haematology | 2015

von Frederiksen, H. | Farkas, D. | Christiansen, C. | +4

CommentIn: Lancet Haematol. 2015 Jul;2(7):e272-3. - PMID 26688382

110

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms

enthalten in: Clinical case reports | 2015

von Bjørn, M. | Hasselbalch, H.